Treatment patterns, health care resource use and outcomes in metastatic triple-negative breast cancer in Germany: retrospective chart review study (OBTAIN)

References

• Ferlay J, Soerjomataram I, Dikshit R. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–1948.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142–150.
   PubMed Web of Science ®Google Scholar
• Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer. 2007;110:876–884.
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721–1728.
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434.
   PubMed Web of Science ®Google Scholar
• Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010;17:173–176.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–1281.
   PubMed Web of Science ®Google Scholar
• Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16(Suppl 1):1–11.
   PubMed Web of Science ®Google Scholar
• Andre F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23:vi46–vi51.
   PubMed Web of Science ®Google Scholar
• Palmieri C, Krell J, James CR, et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:561–574.
   PubMed Web of Science ®Google Scholar
• Vidula N, Bardia A. Targeted therapy for metastatic triple negative breast cancer: the next frontier in precision oncology. Oncotarget. 2017;8:106167–106168.
   PubMedGoogle Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. JCO. 2016;34:2460–2467.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121.
   PubMed Web of Science ®Google Scholar
• Houts AC, Olufade T, Shenolikar R, et al. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings. Canc Treat Res Commun. 2019;19:100121.
   PubMedGoogle Scholar
• Quek RGW, Mardekian J. Clinical outcomes, treatment patterns, and health resource utilization among metastatic breast cancer patients with Germline BRCA1/2 mutation: a real-world retrospective study. Adv Ther. 2019;36:708–720.
   PubMed Web of Science ®Google Scholar
• Schwartz KL, Simon MS, Bylsma LC, et al. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: a SEER–Medicare historical cohort study in elderly women in the United States. Cancer. 2018;124:2104–2114.
   PubMed Web of Science ®Google Scholar
• Robert Koch Institut: Zentrum für Krebsregisterdaten [Internet]. Brustkrebs; 2014 [cited 2018 Mar 19]. Available from: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html
   Google Scholar
• Oualla K, El-Zawahry HM, Arun B, et al. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol. 2017;9:493–511.
   PubMed Web of Science ®Google Scholar
• Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies. Asia-Pac J Clin Oncol. 2018;14:32–39.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015;13:448–475.
   PubMed Web of Science ®Google Scholar
• Engel C, Rhiem K, Hahnen E, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018;18:265.
   PubMed Web of Science ®Google Scholar
• Parinyanitikul N, Lei X, Chavez-MacGregor M, et al. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer. 2015;15:153–160.
   PubMed Web of Science ®Google Scholar
• Yao H, He G, Yan S, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8:1913–1924.
   PubMedGoogle Scholar
• Andreopoulou E, Kelly CM, McDaid HM. Therapeutic advances and new directions for triple-negative breast cancer. Breast Care. 2017;12:21–28.
   PubMed Web of Science ®Google Scholar
• Jitariu AA, Cimpean AM, Ribatti D, et al. Triple negative breast cancer: the kiss of death. Oncotarget. 2017;8:46652–46662.
   PubMedGoogle Scholar
• Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol. 2011;18:180–190.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012;133:1067–1075.
   PubMed Web of Science ®Google Scholar
• Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the Geparquinto study (GBG 44). Ann Oncol. 2013;24:2978–2984.
   PubMed Web of Science ®Google Scholar
• Baser O, Wei W, Henk HJ, et al. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry. Curr Med Res Opin. 2012;28:419–428.
   PubMed Web of Science ®Google Scholar
• Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9:29–33.
   PubMed Web of Science ®Google Scholar
• Vassar M, Holzmann M. The retrospective chart review: important methodological considerations. J Educ Eval Health Prof. 2013;10:12.
   PubMedGoogle Scholar